Antisense oligonucleotides for the treatment of dyslipidaemia

European Heart Journal

Volumn 33, Issue 12, 2012, Pages 1451-1458

  Visser, Maartje E ^a   Witztum, Joseph L ^b   Stroes, Erik S G ^a   Kastelein, John J P ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Antisense oligonucleotides; ApoB; Cardiovascular disease; Hypercholesterolaemia; Lp(a); Mipomersen; PCSK9

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; CYTOCHROME P450; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KEXIN; LIPOPROTEIN; LIPOPROTEIN A; LOCKED NUCLEIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; MIPOMERSEN; NUCLEASE; PLACEBO; PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9; RIBONUCLEASE H; SIMVASTATIN; SMALL INTERFERING RNA; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ADD ON THERAPY; ANTISENSE THERAPY; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SPECIFICITY; DRUG TRANSPORT; DRUG WITHDRAWAL; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; FATTY LIVER; FLU LIKE SYNDROME; HUMAN; HYBRIDIZATION; HYPERCHOLESTEROLEMIA; HYPERPIGMENTATION; HYPOBETALIPOPROTEINEMIA; INJECTION SITE ERYTHEMA; LIPID ABSORPTION; LIPID LIVER LEVEL; LIPID METABOLISM; MONOTHERAPY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYPHARMACY; PRIMARY HYPERCHOLESTEROLEMIA; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RNA DEGRADATION; RNA TRANSLATION; SIDE EFFECT; WATSON CRICK HYBRIDIZATION;

ANIMALS; APOLIPOPROTEIN B-100; APOLIPOPROTEIN C-III; APOPROTEIN(A); CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DYSLIPIDEMIAS; HAPLORHINI; HUMANS; HYPOLIPIDEMIC AGENTS; MICE; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; PROPROTEIN CONVERTASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SERINE ENDOPEPTIDASES;

EID: 84863582389     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehs084     Document Type: Review

References (39)

1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment III) final report. Circulation 2002;106:3143-3421.
2. Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 2010;50:259-293.
3. Davis RA. Cell and molecular biology of the assembly and secretion of apolipoprotein B-containing lipoproteins by the liver. Biochim Biophys Acta 1999;1440: 1-31. (Pubitemid 29406146)
4. Goldstein J, Hobbs H, Brown M. Familial hypercholesterolemia. In: Valle D, Scriber CR, Beaudet A (eds). The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York: McGraw Hill; 2001, p2863-2913.
5. Sankatsing RR, Fouchier SW, de HS, Hutten BA, de GE, Kastelein JJ, Stroes ES. Hepatic and cardiovascular consequences of familial hypobetalipoproteinemia. Arterioscler Thromb Vasc Biol 2005;25:1979-1984. (Pubitemid 41243472)
6. Schonfeld G, Lin X, Yue P. Familial hypobetalipoproteinemia: genetics and metabolism. Cell Mol Life Sci 2005;62:1372-1378. (Pubitemid 40853825)
7. Lonardo A, Lombardini S, Scaglioni F, Carulli L, Ricchi M, Ganazzi D, Adinolfi LE, Ruggiero G, Carulli N, Loria P. Hepatic steatosis and insulin resistance: does etiology make a difference? J Hepatol 2006;44:190-196. (Pubitemid 41772534)
8. Tarugi P, Averna M, Di LE, Cefalu AB, Noto D, Magnolo L, Cattin L, Bertolini S, Calandra S. Molecular diagnosis of hypobetalipoproteinemia: an ENID review. Atherosclerosis 2007;195:e19-e27. (Pubitemid 350087974)
9. Elovson J, Chatterton JE, Bell GT, Schumaker VN, Reuben MA, Puppione DL, Reeve JR Jr, Young NL. Plasma very low density lipoproteins contain a single molecule of apolipoprotein B. J Lipid Res 1988;29:1461-1473. (Pubitemid 19013040)
10. Geary RS. Antisense oligonucleotide pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol 2009;5:381-391.
11. Crooke RM, Baker BF,Wedel M. Cardiovascular Therapeutic Applications in Antisense Drug Technology; Principles, Strategies and Applications. 2nd ed. Boca Raton, Florida: CRC Press; 2008, 601-639.
12. Crooke RM, Graham MJ, Lemonidis KM, Whipple CP, Koo S, Perera RJ. An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J Lipid Res 2005;46:872-884.
13. Mullick AE, Fu W, Graham MJ, Lee RG, Witchell D, Bell TA, Whipple CP, Crooke RM. Antisense oligonucleotide reduction of apoB-ameliorated atherosclerosis in LDL receptor-deficient mice. J Lipid Res 2011;52:885-896.
14. Yu RZ, Kim TW, Hong A, Watanabe TA, Gaus HJ, Geary RS. Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab Dispos 2007;35:460-468. (Pubitemid 46333910)
15. Yu RZ, Geary RS, Flaim JD, Riley GC, Tribble DL, vanVliet AA,Wedel MK. Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2?-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe. Clin Pharmacokinet 2009;48:39-50.
16. Chandler CE, Wilder DE, Pettini JL, Savoy YE, Petras SF, Chang G, Vincent J, Harwood HJ Jr. CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans. J Lipid Res 2003;44: 1887-1901. (Pubitemid 37356661)
17. Kastelein JJ, Wedel MK, Baker BF, Su J, Bradley JD, Yu RZ, Chuang E, Graham MJ, Crooke RM. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 2006;114:1729-1735. (Pubitemid 44607121)
18. Akdim F, Tribble DL, Flaim JD, Yu R, Su J, Geary RS, Baker BF, Fuhr R, Wedel MK, Kastelein JJ. Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia. Eur Heart J 2011;32:2650-2659.
19. Akdim F, Stroes ES, Sijbrands EJ, Tribble DL, Trip MD, Jukema JW, Flaim JD, Su J, Yu R, Baker BF, Wedel MK, Kastelein JJ. Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. J Am Coll Cardiol 2010;55:1611-1618.
20. Akdim F, Visser ME, Tribble DL, Baker BF, Stroes ES, Yu R, Flaim JD, Su J, Stein EA, Kastelein JJ. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on lowdensity lipoprotein cholesterol in patients with familial hypercholesterolemia. Am J Cardiol 2010;105:1413-1419.
21. Raal FJ, Santos RD, Blom DJ, Marais AD, Charng MJ, Cromwell WC, Lachmann RH, Gaudet D, Tan JL, Chasan-Taber S, Tribble DL, Flaim JD, Crooke ST. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010;375:998-1006.
22. Stein E, Dufour R, Gagne C, Gaudet D, East C, Tribble D, Donovan J, Chin W, Mcgowan M. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of mipomersen as add-on therapy in heterozygous familial hypercholesterolemia patients with coronary artery disease. Eur Heart J 2010;31(Suppl. 1):898.
23. Tardif JC, Mcgowan M, Ceska R, Burgess LJ, Soran H, Gouni-Berthold I, Wagnegener G, Chasan-Taber S. Apolipoprotein B synthesis inhibition by mipomersen reduces LDL-C when added to maximally tolerated lipid-lowering medication in patients with severe heterozygous hypercholesterolemia. J Am Coll Cardiol 2011;57:E492.
24. Cromwell W, Thomas GS, Boltje I, Chin W, Davidson M. Safety and efficacy of mipomersen administered as add-on therapy in patients with hypercholesterolemia and high cardiovascular risk. J Am Coll Cardiol 2011;57:E504.
25. Taylor S, Grimes P, Lim J, Im S, Lui H. Postinflammatory hyperpigmentation. J Cutan Med Surg 2009;13:183-191.
26. Cuchel M, Bloedon LT, Szapary PO, Kolansky DM, Wolfe ML, Sarkis A, Millar JS, Ikewaki K, Siegelman ES, Gregg RE, Rader DJ. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med 2007;356: 148-156. (Pubitemid 46089675)
27. Visser ME, Akdim F, Tribble DL, Nederveen AJ, Kwoh TJ, Kastelein JJ, Trip MD, Stroes ES. Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia. J Lipid Res 2010;51: 1057-1062.
28. Zaid A, Roubtsova A, Essalmani R, Marcinkiewicz J, Chamberland A, Hamelin J, Tremblay M, Jacques H, JinW, Davignon J, Seidah NG, Prat A. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology 2008;48:646-654.
29. Abifadel M, Rabes JP, Devillers M, Munnich A, Erlich D, Junien C, Varret M, Boileau C. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum Mutat 2009;30: 520-529.
30. Zhao Z, Tuakli-Wosornu Y, Lagace TA, Kinch L, Grishin NV, Horton JD, Cohen JC, Hobbs HH. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet 2006;79:514-523. (Pubitemid 44384260)
31. Hooper AJ, Marais AD, Tanyanyiwa DM, Burnett JR. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis 2007;193:445-448. (Pubitemid 47058112)
32. Alborn WE, Cao G, Careskey HE, Qian YW, Subramaniam DR, Davies J, Conner EM, Konrad RJ. Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol. Clin Chem 2007;53:1814-1819. (Pubitemid 47509675)
33. Graham MJ, Lemonidis KM, Whipple CP, Subramaniam A, Monia BP, Crooke ST, Crooke RM. Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J Lipid Res 2007;48:763-767. (Pubitemid 46557881)
34. Straarup EM, Fisker N, Hedtjarn M, Lindholm MW, Rosenbohm C, Aarup V, Hansen HF, Orum H, Hansen JB, Koch T. Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates. Nucleic Acids Res 2010;38:7100-7111.
35. Gupta N, Fisker N, Asselin MC, Lindholm M, Rosenbohm C, Orum H, Elmen J, Seidah NG, Straarup EM. A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo. PLoS One 2010;5:e10682.
36. Frank-Kamenetsky M, Grefhorst A, Anderson NN, Racie TS, Bramlage B, Akinc A, Butler D, Charisse K, Dorkin R, Fan Y, Gamba-Vitalo C, Hadwiger P, Jayaraman M, John M, Jayaprakash KN, Maier M, Nechev L, Rajeev KG, Read T, Rohl I, Soutschek J, Tan P, Wong J, Wang G, Zimmermann T, de FA, Vornlocher HP, Langer R, Anderson DG, Manoharan M, Koteliansky V, Horton JD, Fitzgerald K. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci USA 2008;105:11915-11920.
37. Pollin TI, Damcott CM, Shen H, Ott SH, Shelton J, Horenstein RB, Post W, McLenithan JC, Bielak LF, Peyser PA, Mitchell BD, Miller M, O'Connell JR, Shuldiner AR. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science 2008;322:1702-1705.
38. Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, Parish S, Barlera S, Franzosi MG, Rust S, Bennett D, Silveira A, Malarstig A, Green FR, Lathrop M, Gigante B, Leander K, de FU, Seedorf U, Hamsten A, Collins R, Watkins H, Farrall M. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009;361:2518-2528.
39. Merki E, Graham M, Taleb A, Leibundgut G, Yang X, Miller ER, Fu W, Mullick AE, Lee R, Willeit P, Crooke RM, Witztum JL, Tsimikas S. Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice. J Am Coll Cardiol 2011;57:1611-1621.